<div><div></div><div><span><p><span>BiomX Inc. reported results for the first quarter of 2026 showing a larger net loss versus the year-ago quarter as the company shifts its strategy and begins integrating recent defense-technology acquisitions.</span></p><p><strong><span>Financial Highlights</span></strong></p><ul><li><span>Net income: $(19.14M) for Q1 2026, versus $(7.66M) in Q1 2025.</span></li><li><span>Diluted EPS: $(7.38) for Q1 2026, versus $(6.27) in Q1 2025.</span></li></ul><p><strong><span>Business Highlights</span></strong></p><ul><li><span>Strategy shift: BiomX pivoted from biopharma to defense and security technology, acquiring Zorronet and a 60% stake in DFSL and forming a new unit, X Security.</span></li><li><span>Product momentum: DFSL’s LADAR and Zorronet’s AI platforms are positioned for deployments in counter-UAS, perimeter security and command-and-control video analytics.</span></li><li><span>Operational rollout: Management expects DFSL and Zorronet to begin contributing revenue and cash flow starting in Q2 2026; X Security is funded for 2026 operations.</span></li><li><span>Customer traction: Zorronet has active pilots and projects with Elbit, Rafael, IDF bases, and distribution agreements for stadium and UAE deployments.</span></li><li><span>R&amp;D/IP: The company retains the APT legacy patent portfolio and related grants and is exploring commercialization, partnerships or out-licensing for remaining biotech assets.</span></li></ul><p><span>Original SEC Filing: </span>BiomX Inc. [ PHGE ] - 10-Q - May. 20, 2026</p><section><b><span class="heading-JaE7wgR2">Disclaimer</span></b><div><span>This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.</span></div></section></span></div></div>

PHGE

DFNS

<p>BiomX Inc. reported a net loss of $19.14M for Q1 2026, up from $7.66M in Q1 2025, as it shifts focus from biopharma to defense technology. The company acquired Zorronet and a 60% stake in DFSL, launching a new unit, X Security. Revenue contributions from these acquisitions are expected starting Q2 2026, with active projects underway with major clients.</p>

TradingView

BiomX

T3 Defense

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

Elbit

BiomX Inc. 1Q 2026: Net income $(19.14M), EPS $(7.38) — 10-Q Summary